Why innovation in science must be matched with innovation in operations.
Cell and gene therapy (CGT) manufacturers are transforming medicine with personalized, high-precision therapies. But the same qualities that make CGT groundbreaking also make operations uniquely challenging: small-batch production, narrow therapeutic windows, evolving facilities, and heightened regulatory scrutiny. In this environment, asset management isn’t just a support function—it’s mission-critical.
Our whitepaper, Mastering Asset Management in Cell & Gene Therapy, explores the trends shaping CGT manufacturing, the unique needs of these facilities, and the must-have features of a purpose-built EAM/CMMS solution. You’ll learn how the right platform helps CGT organizations minimize downtime, ensure audit readiness, scale from clinical to commercial production, and integrate seamlessly with QA, MES, and LIMS systems.
Download your copy today and discover how next-generation asset management can help CGT companies align operational excellence with scientific innovation—protecting patients, accelerating scale-up, and enabling long-term success.